TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01289392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Appliance (OA)
Description: Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
Study: NCT04196296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation
Description: Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
Study: NCT02803879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry
Study: NCT01071551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-style intervention
Description: The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity only
Description: Children allocated to this group will attend 20 physical activity classes.
Study: NCT01835548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT0102
Description: NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching ODT placebo was given once daily.
Study: NCT03284697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping with Ca(OH)2
Description: Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp Capping With MTA
Description: MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
Study: NCT03419260

Intervention type: OTHER
Intervention: Clinically indicated EEG monitoring.
Description: Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
Study: NCT03736460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
Study: NCT03428542

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yin yoga
Description: Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YOMI
Description: 30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments.
Study: NCT04731324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYIL1 capsule
Description: NLRP3 inflammasome inhibitor
Study: NCT00895050

Intervention type: OTHER
Intervention: Review of clinical records
Study: NCT01740934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc Cream
Description: subject will apply active cream topically, twice per day according to instructions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: subject will apply placebo cream topically, twice per day according to instructions
Study: NCT00735319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubinometer
Description: For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
Study: NCT02711527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupunture group A
Description: Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupunture group B
Description: Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion.
Study: NCT04499209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG005
Description: XG005 Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Naproxen and Pregabalin
Description: Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Capsule
Study: NCT02442297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2-specific T cells
Description: Dosing Schedule 1:~Cycle 1 A: 1x10\^7 cells~Cycle 2 A: 1x10\^7 cells~Cycle 3 A: 1x10\^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 B: 3x10\^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 C: 1x10\^8 cells~Subsequent cycles\*~\*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease.
Study: NCT01169038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levaquin; ethambutol; rifampin and azithromycin.
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway.
Study: NCT01898845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study: NCT01016054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion
Study: NCT01488448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% sodium chloride
Description: 4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
Study: NCT02703285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound
Description: task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
Study: NCT03438643

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Blood samples (42mL) will be taken before and during treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: skin biopsy will be taken before and during treatment.
Study: NCT01614262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring with treatment algorithm
Description: those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring with treatment algorithm
Description: those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
Study: NCT04218994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flossing technique
Description: Subjects instructed on flossing technique
Study: NCT03625648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02434809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Implantation
Description: Calypso transponders

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-Beam CT-Guided

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation treatments
Study: NCT03941093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Description: Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Description: Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Study: NCT04088994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOT Pathological Model Experimental Group
Description: The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AOT Healthy Model Control Group
Description: The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
Study: NCT04569214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ320
Description: Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ320
Description: Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
Study: NCT01289392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: aerobic and resistance Physical exercise, three times a week, for four months
Study: NCT01943864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (single tablet)
Description: The drug substance is blended with inert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (single tablet)
Description: The drug substance is blended with inert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (Multiple tablet)
Description: The drug substance is blended with inert
Study: NCT02572661

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation in Squamous Head and Neck Cancer
Study: NCT03392519

Intervention type: OTHER
Intervention: Chronic stroke
Description: MRI data acquisition and behavioral test
Study: NCT04209868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection
Description: As per arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride 20mL Injection
Description: As per arm description
Study: NCT03554499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bichectomy with hydrodissection
Description: Intraoral removal of buccal fat pads using hydrodissection technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bichectomy
Description: Intraoral removal of buccal fat pads using conventional technique
Study: NCT05913557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behavior Therapy (RO DBT)
Description: Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
Study: NCT02097706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMDA receptor antagonist (active drug)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose packed capsule (inert/inactive arm)
Study: NCT03997539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of physician's choice
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: vinorelbine
Study: NCT04330508

Intervention type: OTHER
Intervention: Depression and Cognitive Tests
Description: Health Related Quality of Life, neurocognitive tests, PHES

Intervention type: OTHER
Intervention: Depression and Cognitive Tests
Description: Health Related Quality of Life, neurocognitive tests, PHES
Study: NCT02111824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMIG System
Description: Minimally Invasive MultiModality Imaging Guidance System (MIMIG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMIG System
Description: Minimally Invasive MultiModality Imaging Guidance System (MIMIG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
Study: NCT02389413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ912 oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06691607

Intervention type: OTHER
Intervention: Serum NGAL level
Description: serum NGAL level

Intervention type: OTHER
Intervention: Serum NGAL level
Description: serum NGAL level
Study: NCT04121273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:~Dose 1: 1x10\^7/m2~Dose 2: 3x10\^7/m2~Dose 3: 1x10\^8/m2~The cell numbers are calculated according to CAR-positive T cells.
Study: NCT00783718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study: NCT04462913

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study: NCT00547664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex recombinant , morphine, saline
Description: Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hylenex recombinant , morphine, saline
Description: Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
Study: NCT01632865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting
Description: Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
Study: NCT02953548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.